Merck - 55 Year Stock Price History | MRK

Historical daily share price chart and data for Merck since 1970 adjusted for splits and dividends. The latest closing stock price for Merck as of January 08, 2025 is 99.85.
  • The all-time high Merck stock closing price was 131.04 on June 24, 2024.
  • The Merck 52-week high stock price is 134.63, which is 34.8% above the current share price.
  • The Merck 52-week low stock price is 94.48, which is 5.4% below the current share price.
  • The average Merck stock price for the last 52 weeks is 118.07.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Merck Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2025 99.7800 99.1700 101.0200 99.1400 99.8500 0.37%
2024 116.4267 110.2279 131.0370 95.5366 99.4800 -6.26%
2023 103.6951 105.2530 112.8746 96.8113 106.1202 1.00%
2022 83.6701 70.5485 106.1811 67.4648 105.0731 49.38%
2021 69.6528 71.7076 82.3238 63.9221 70.3374 -2.92%
2020 70.3661 79.0202 79.0202 57.4602 72.4516 -7.21%
2019 69.5403 63.1810 78.7626 60.9493 78.0843 22.26%
2018 52.7777 45.5797 65.8419 43.5366 63.8664 40.00%
2017 49.5681 47.3096 53.1827 43.4882 45.6202 -1.47%
2016 44.4588 39.9863 50.7071 37.0224 46.3029 15.05%
2015 42.3066 42.1617 46.4671 36.5703 40.2454 -3.87%
2014 41.4738 35.3989 45.2759 35.3989 41.8668 16.95%
2013 32.5306 28.5083 35.7994 28.1704 35.7994 26.80%
2012 27.8453 25.3538 32.7530 24.6984 28.2324 13.13%
2011 22.0158 22.7834 25.0890 19.2688 24.9566 9.54%
2010 22.2453 22.4343 24.8711 19.4870 22.7834 2.86%
2009 17.4877 17.8226 23.0344 12.2656 22.1494 26.73%
2008 20.7352 31.5694 33.3193 13.3534 17.4777 -45.34%
2007 27.4648 23.5044 33.4404 22.9277 31.9766 37.36%
2006 20.0522 16.8013 24.4656 16.8013 23.2801 42.66%
2005 15.2972 15.2563 17.2524 13.0923 16.3191 4.04%
2004 20.0263 22.1142 23.0905 12.5176 15.6857 -27.76%
2003 23.7510 25.2045 27.7280 18.9222 21.7147 -11.35%
2002 23.0511 25.2114 27.3079 16.6718 24.4949 -1.26%
2001 29.6116 38.3733 38.3733 24.1187 24.8064 -35.79%
2000 30.1691 27.4273 39.0954 21.9811 38.6332 41.78%
1999 29.4499 29.9096 34.6126 24.5175 27.2489 -7.47%
1998 25.5110 21.1538 31.6866 20.2298 29.4503 41.32%
1997 18.3908 15.4177 21.0948 15.4177 20.8393 35.61%
1996 12.9830 12.1402 16.1795 10.8239 15.3675 23.92%
1995 9.2356 7.0694 12.6372 6.7231 12.4010 76.57%
1994 6.0206 6.2717 7.2536 5.0936 7.0233 14.82%
1993 6.1434 7.5779 7.5779 5.0305 6.1169 -18.35%
1992 8.2932 9.3917 9.5323 7.0643 7.4915 -20.29%
1991 6.7044 4.9548 9.3985 4.5535 9.3985 88.88%
1990 4.3168 4.2442 4.9759 3.6465 4.9759 18.95%
1989 3.7574 3.0167 4.2935 3.0167 4.1832 37.47%
1988 2.8455 2.8163 3.1146 2.4930 3.0431 12.05%
1987 2.8804 2.1589 3.7267 2.1589 2.7158 27.96%
1986 1.6381 1.1823 2.2189 1.1598 2.1224 80.83%
1985 0.9407 0.7979 1.1737 0.7743 1.1737 45.75%
1984 0.7592 0.7743 0.8310 0.6832 0.8053 4.00%
1983 0.7791 0.7196 0.8931 0.7025 0.7743 6.81%
1982 0.6586 0.7325 0.7518 0.5504 0.7249 -0.17%
1981 0.7447 0.7368 0.8771 0.6554 0.7261 0.00%
1980 0.6232 0.6061 0.7261 0.5033 0.7261 17.30%
1979 0.5784 0.5815 0.6329 0.5365 0.6190 6.85%
1978 0.4934 0.4594 0.5922 0.4123 0.5793 21.83%
1977 0.4811 0.5740 0.5740 0.4316 0.4755 -18.52%
1976 0.6127 0.5965 0.6886 0.5397 0.5836 -1.63%
1975 0.6380 0.5761 0.7325 0.5033 0.5933 4.33%
1974 0.6157 0.6886 0.7335 0.4198 0.5687 -17.79%
1973 0.7653 0.7753 0.8610 0.6661 0.6918 -9.39%
1972 0.6543 0.5365 0.7668 0.5365 0.7635 43.73%
1971 0.4541 0.4069 0.5601 0.4069 0.5312 25.25%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $250.864B $60.115B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $738.634B 76.51
Novo Nordisk (NVO) Denmark $392.749B 28.32
Johnson & Johnson (JNJ) United States $346.746B 14.06
AbbVie (ABBV) United States $317.096B 16.69
AstraZeneca (AZN) United Kingdom $204.270B 17.38
Novartis AG (NVS) Switzerland $198.554B 13.20
Pfizer (PFE) United States $150.799B 10.31
Sanofi (SNY) $122.299B 11.08
Bayer (BAYRY) Germany $19.413B 3.11
Innoviva (INVA) United States $1.089B 9.06